Advanced in Cholangiocarcinoma (Bile Duct Cancer)

Stephen L. Chan

State Key Laboratory Of Translational Oncology, Hong Kong, 
Sar, CN 
Advanced in Cholangiocarcinoma (Bile Duct Cancer)
State Key Laboratory Of Translational Oncology, Hong Kong, 
Sar, CN 
OverviewLocationsClinical Research

Overview

Stephen Chan practices in Sar, China. Mr. Chan is rated as an Advanced expert by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). His top areas of expertise are Liver Cancer, Trophoblastic Tumor Placental Site, Cholangiocarcinoma (Bile Duct Cancer), Hepato-Pancreato-Biliary Surgery, and Hepatectomy.

His clinical research consists of co-authoring 214 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 12 articles in the study of Cholangiocarcinoma (Bile Duct Cancer).

Gender
Male

Locations

State Key Laboratory Of Translational Oncology, Hong Kong, Sar, China
Other Locations
State Key Laboratory Of Translational Oncology, Hong Kong, China
Kongpao, China
Lika, China
Lo, China
Yangzhou, China
Shenzhen, 518055, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase II Trial of PEG-BCT-100 as the Second-line Therapy Following Sorafenib in Patients With Advanced Hepatocellular Carcinoma
A Phase II Trial of PEG-BCT-100 as the Second-line Therapy Following Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Enrollment Status: Completed
Publish Date: August 09, 2021
Intervention Type: Biological
Study Phase: Phase 2
Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy
Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy
Enrollment Status: Completed
Publish Date: July 28, 2021
Intervention Type: Biological
Study Drug: Recombinant Epstein-Barr Virus Vaccine
Study Phase: Phase 2
View 1 Less Clinical Trial

214 Total Publications

Editorial: Immune Checkpoint Inhibitors and HBV Reactivation in Liver Cancer-Reassurance With Vigilance. Authors' Reply.
Editorial: Immune Checkpoint Inhibitors and HBV Reactivation in Liver Cancer-Reassurance With Vigilance. Authors' Reply.
Journal: Alimentary pharmacology & therapeutics
Published: September 30, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Chan's expertise for a condition
ConditionClose
    View All 17 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile